CureVac Full Year 2023 Earnings: Misses Expectations

Yahoo FinanceApr 27 20:33

UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating

UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating.

MT NewswiresApr 26 23:45

Curevac's Market Forecast Risks: Miscalculations and Trial Participant Challenges Threaten Profitability

TipRanksApr 26 14:01

Curevac Cut to Market Perform From Outperform by Leerink Partners

Curevac Cut to Market Perform From Outperform by Leerink Partners

Dow JonesApr 25 21:23

Leerink Partners Downgrades CureVac to Market Perform, Lowers Price Target to $4

Leerink Partners analyst Mani Foroohar downgrades CureVac from Outperform to Market Perform and lowers the price target from $12 to $4.

Analyst UpgradesApr 25 21:12

CureVac Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 60% Leerink Partners $12 → $4 Downgrades Outperform → Market Perform 04/05/2024 — Guggenheim R

BenzingaApr 25 21:10